INS and metabolic syndrome: RBP4 is recognized as a negative acute inflammatory reactant and as a novel adipokine, whose levels increase in insulin-resistant conditions, such as obesity, metabolic syndrome, type 2 diabetes mellitus [45], as well as cardiovascular diseases [46].